XML 55 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SEGMENT INFORMATION (Tables)
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Schedule of financial information regarding the company's reportable segments
Financial information regarding our reporting segments is shown below:
Three Months Ended March 31,20242023
Total Sales:
Aptar Pharma$407,490 $356,111 
Aptar Beauty334,880 333,338 
Aptar Closures182,697 180,439 
Total Sales$925,067 $869,888 
Less: Intersegment Sales:
Aptar Pharma$197 $65 
Aptar Beauty7,560 6,949 
Aptar Closures1,862 2,807 
Total Intersegment Sales$9,619 $9,821 
Net Sales:
Aptar Pharma$407,293 $356,046 
Aptar Beauty327,320 326,389 
Aptar Closures180,835 177,632 
Net Sales$915,448 $860,067 
Adjusted EBITDA (1):
Aptar Pharma$132,178 $109,298 
Aptar Beauty41,134 37,205 
Aptar Closures27,161 26,008 
Corporate & Other, unallocated(21,641)(18,836)
Acquisition-related costs (2)— (255)
Restructuring Initiatives (3)(3,480)(11,524)
Net unrealized investment gain (4)592 188 
Depreciation and amortization(64,349)(59,259)
Interest Expense(10,175)(10,228)
Interest Income2,898 672 
Income before Income Taxes$104,318 $73,269 
________________________________________________
(1)We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items.
(2)Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments) (see Note 17 – Acquisitions for further details).
(3)Restructuring Initiatives includes expense items for the three months ended March 31, 2024 and 2023 as follows (see Note 19 – Restructuring Initiatives for further details):
Three Months Ended March 31,20242023
Restructuring Initiatives by Plan:
Optimization initiative$3,497 $11,540 
Prior year initiatives(17)(16)
Total Restructuring Initiatives$3,480 $11,524 
Restructuring Initiatives by Segment:
Aptar Pharma$24 $1,131 
Aptar Beauty2,710 9,291 
Aptar Closures760 522 
Corporate & Other(14)580 
Total Restructuring Initiatives$3,480 $11,524 
(4)Net unrealized investment gain (loss) represents the change in fair value of our investment in PCT (see Note 18 – Investment in Equity Securities for further details).
Schedule of restructuring initiatives Restructuring Initiatives includes expense items for the three months ended March 31, 2024 and 2023 as follows (see Note 19 – Restructuring Initiatives for further details):
Three Months Ended March 31,20242023
Restructuring Initiatives by Plan:
Optimization initiative$3,497 $11,540 
Prior year initiatives(17)(16)
Total Restructuring Initiatives$3,480 $11,524 
Restructuring Initiatives by Segment:
Aptar Pharma$24 $1,131 
Aptar Beauty2,710 9,291 
Aptar Closures760 522 
Corporate & Other(14)580 
Total Restructuring Initiatives$3,480 $11,524